# BPC-157 TB-500: The Wolverine Peptide Blend, Read Channel by Channel > BPC-157 TB-500 is the two-peptide "Wolverine" blend pairing a cytoprotective, angiogenic pentadecapeptide with the actin-binding TB-500 fragment of Thymosin Beta-4. The constituent literature and the access record, cited. One channel is BPC-157, a cytoprotective angiogenic pentadecapeptide; the other is TB-500, the actin-binding fragment of Thymosin Beta-4. This console reads each leg against its own studies — and prints every blend-level gap in plain sight. ## BPC-157 TB-500: two peptides on one console BPC-157 TB-500 is not one molecule. It is a research-community pairing of two distinct synthetic peptides, marketed and discussed under the name "Wolverine." The first channel is BPC-157 (Body Protection Compound 157), a 15-amino-acid pentadecapeptide, sequence `GEPPPGKPADDAGLV`, ~1419.5 Da, derived from a protein found in human gastric juice [1]. The second channel is TB-500, a synthetic N-acetylated heptapeptide, `Ac-LKKTETQ`, ~889 Da, copied from residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4 [3]. The two peptides do different jobs. BPC-157 acts mostly outside the cell: it up-regulates VEGFR2 and drives a downstream Akt-eNOS angiogenic and cytoprotective signal [2]. TB-500 acts inside the cell: its `LKKTETQ` motif binds a single molecule of monomeric G-actin and sequesters it, regulating the cytoskeletal dynamics that move cells during repair [3]. Those mechanisms are described as complementary and largely non-overlapping — which is exactly the argument the "Wolverine" pairing rests on. That argument has a ceiling, and this site states it on every page. No controlled study has been published that gives the two peptides together and measures a combined effect. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies and never mentions TB-500 or any combination at all [5]. The literature below is real, cited, and overwhelmingly preclinical and single-compound. Read it that way. ## BPC 157 TB 500: naming and the Wolverine stack Search traffic spells this blend several ways — `BPC-157 TB-500`, `BPC 157 TB 500` without hyphens, "BPC-157 and TB-500," or just "Wolverine." They all point at the same two peptides. The hyphenated and unhyphenated forms are interchangeable shorthand; neither is a chemical name, because the blend has no single chemical name, CAS number, or molecular weight. The values that exist are per-constituent: BPC-157 at CAS `137525-51-0` and PubChem CID `108101`; TB-500 as the `Ac-LKKTETQ` fragment of Thymosin Beta-4 (human, UniProt `P62328`) [1][3]. The "Wolverine" label is research-community branding, borrowed from the comic-book character's rapid healing — not a product approved by any regulator and not a name that appears in the scientific literature. Commercial vials are commonly labeled with a combined per-vial mass, such as 10 mg BPC-157 plus 10 mg TB-500, but that ratio is a marketing convention, not a clinically validated composition [1]. If you want [how BPC-157 and TB-500 work](/how-it-works) at the mechanism level, that is the next page. ## The BPC-157 TB-500 stack ('Wolverine') The "stack" framing comes from athlete and research-peptide forums, where BPC-157 and TB-500 are run together on the theory that two repair signals beat one. As a mechanism story, the logic is coherent: BPC-157 supplies a local angiogenic and cytoprotective signal while TB-500 supplies a cytoskeletal cell-migration signal, so in principle they address different steps of the same repair process [2][3][4]. As an evidence story, the stack is unproven. There is no published combination dose, no defined `BPC-157:TB-500` ratio with a controlled-trial basis, and no head-to-head endpoint demonstrating that the pair outperforms either peptide alone. The 2025 BPC-157 systematic review found "no clinical safety data" for BPC-157 by itself and rated the musculoskeletal evidence at the lowest tiers (level IV-V) [5]. A blend inherits those limits twice over. The honest summary: a plausible two-mechanism rationale, sitting on top of two thin single-compound literatures, with zero combination data. ## What the constituent research actually shows Each channel has a flagship preclinical result. For BPC-157: in a fully transected rat Achilles tendon, BPC-157 at `10 microg/kg` or `10 ng/kg` improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, and in cultured tendocytes it reversed 4-hydroxynonenal-induced growth inhibition into stimulation [1]. For its vascular leg, BPC-157 up-regulated VEGFR2 and promoted VEGFR2 internalization with downstream Akt-eNOS activation, increasing vessel density and speeding blood-flow recovery in ischemic muscle [2]. For TB-500 and its parent protein: X-ray crystallography of a thymosin beta-4-actin complex (2 angstrom) established that the peptide forms a 1:1 complex with G-actin and caps both ends of the monomer, preventing polymerization [3]. A consolidated review describes full-length Thymosin Beta-4 as binding actin, promoting cell migration and stem-cell activity, reducing myofibroblast number (less scarring), and promoting angiogenesis [4]. One caveat travels with every TB-500 claim: most efficacy data attributed to "TB-500" were generated with the full-length 43-residue protein, not the `Ac-LKKTETQ` 7-mer that is actually sold [4]. The deep dives sit on the dedicated pages — [the difference between BPC-157 and TB-500](/how-it-works), [the preclinical research evidence](/research), and [research dosing context](/dosage). For human availability, see [Wolverine legal status and 503A compounding](/legal-status). --- Two peptide channels read on one console — BPC-157 and TB-500 traced to their own studies and their own 503A status, every blend-level gap left lit, with no clinic at the terminal and nothing here to dispense.